Australia markets close in 3 hours 48 minutes

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
22.82-0.89 (-3.75%)
At close: 04:00PM EDT
22.80 -0.02 (-0.09%)
After hours: 04:34PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.84B
Enterprise value 3.32B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)7.37
Enterprise value/revenue N/A
Enterprise value/EBITDA -9.15

Trading information

Stock price history

Beta (5Y monthly) 1.53
52-week change 3-27.87%
S&P500 52-week change 3-10.17%
52-week high 341.46
52-week low 319.86
50-day moving average 330.14
200-day moving average 329.08

Share statistics

Avg vol (3-month) 3625.9k
Avg vol (10-day) 3850.11k
Shares outstanding 5156.66M
Implied shares outstanding 6N/A
Float 868.58M
% held by insiders 117.56%
% held by institutions 186.29%
Shares short (27 Feb 2023) 44.82M
Short ratio (27 Feb 2023) 47.17
Short % of float (27 Feb 2023) 410.32%
Short % of shares outstanding (27 Feb 2023) 43.08%
Shares short (prior month 30 Jan 2023) 45.7M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Dec 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-26.94%
Return on equity (ttm)-63.91%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -362.94M
Net income avi to common (ttm)-351.51M
Diluted EPS (ttm)-2.26
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)892.03M
Total cash per share (mrq)5.69
Total debt (mrq)426.92M
Total debt/equity (mrq)81.90
Current ratio (mrq)12.48
Book value per share (mrq)3.33

Cash flow statement

Operating cash flow (ttm)-293.19M
Levered free cash flow (ttm)-164.35M